Scaling advanced therapies from scientific breakthrough to widespread patient access to #CGTs demands collaboration across the entire ecosystem. Joe DePinto will lead discussions at the Alliance for Regenerative Medicine's Evolution of the Cell & Gene Therapy Sector Workshop. The two-day program will examine strategies to scale autologous and allogeneic CGTs, innovations in delivery, and real-world approaches to expanding patient access. Register: https://lnkd.in/e9bJeniW #CellAndGeneTherapy #PatientAccess
InspiroGene by McKesson
Hospitals and Health Care
Irving, Texas 1,007 followers
Bridging the gap between cell and gene therapy innovation and reality.
About us
Backed by the extensive supply chain expertise of McKesson, InspiroGene is focused on enabling manufacturers, payers, and providers to navigate the complex cell and gene therapy (CGT) commercialization landscape to ensure patients can access the life-changing treatments they need. With unparalleled experience in every stage of the CGT life cycle, InspiroGene offers a premier suite of services that are flexible and scalable.
- Website
-
https://inspirogene.com/
External link for InspiroGene by McKesson
- Industry
- Hospitals and Health Care
- Company size
- 10,001+ employees
- Headquarters
- Irving, Texas
- Type
- Public Company
- Founded
- 2022
Locations
-
Primary
Get directions
Irving, Texas 75039, US
Employees at InspiroGene by McKesson
Updates
-
At the Cell and Gene Meeting on the Mesa, Joe DePinto joined industry leaders to discuss what it will take to make CAR-T and other #CGTs truly mainstream: from decentralized care to new quality standards and scalable manufacturing. Read the session summary here: https://lnkd.in/gkVTsaCG #CellAndGeneTherapy #CART #PatientAccess #CGMesa25
-
-
As the #CGT landscape moves from early promise to proven outcomes, the challenge to scale access equitably and sustainably has become more urgent. In his recent Targeted Oncology article, Joe DePinto explores how InspiroGene is helping to address the barriers identified in the 2025 CGT Report. Read the full discussion here: https://lnkd.in/gV6TKi9M
Cell and gene therapy is reaching an inflection point. The industry is shifting from promise to proof, but financial, infrastructure, and geographic barriers still limit patient access. In my recent interview with Targeted Oncology, I discussed the specific challenges and opportunities outlined in the 2025 CGT Report and what InspiroGene by McKesson is doing to break down access barriers. Read it here: https://lnkd.in/esXsJZWY
-
How can managed care organizations prepare for the next wave of cell and gene therapies? Join Elias Pittos, PharmD, BCOP, CSP at #AMCPNexus, where he’ll present his poster, “Integrating Cell and Gene Therapies Into Managed Care: An Analysis of U.S. Payer Insights.” This work highlights payer perspectives shaping how CGTs are evaluated, reimbursed, and integrated into real-world care. #CellAndGeneTherapy #PayerInsights #ManagedCare #AMCPNexus
I’m looking forward to presenting my poster, “Integrating Cell and Gene Therapies Into Managed Care: An Analysis of U.S. Payer Insights,” at #AMCPNexus. If you’ll be in National Harbor, stop by on October 29 to discuss how we can continue advancing access and value-based integration for these transformative therapies. #CellAndGeneTherapy #ManagedCare #PayerInsights
-
-
For Alyssa Heller, Customer Success Executive for Cell, Gene & Advanced Therapies at InspiroGene, the connection to InspiroGene’s work runs deep — as both a CGT professional and a caregiver. In this week’s spotlight, Alyssa shares what fuels her purpose and why she’s excited to help bring innovative therapies to the patients who need them most. #CellAndGeneTherapy #HealthcareInnovation #CGTSolutions
-
Establishing consistent standards is essential to advancing access and safety in cell and gene therapy. AABB’s Cell and Gene Therapy Standards for Pharmacy, which were developed with input from academic, clinical, and industry experts, fill a critical gap for pharmacies managing approved CGT products.
The next era in cell and gene therapy standards is here. 🛡️ AABB is pleased to release the first edition of the Cell and Gene Therapy Standards for Pharmacy, which establish quality systems for pharmacies that dispense approved cell and gene therapy products. The new standards are designed to help pharmacies enhance patient safety, safeguard product integrity and support operational readiness. The standards take effect Oct. 1 and are available in print, digital and bundle editions: https://bit.ly/46lbC7X #Quality #CellTherapy #GeneTherapy #Biotherapies
-
-
As the number of cell and gene therapies grows, so does the complexity of delivering them. Mylove Mortel, MSPH, RN, OCN, Director of Transplant, Cellular Therapy and Advanced Hematology at UChicago Medicine, outlines the institution’s plans to expand #CGT capacity and prevent bottlenecks, and offers insights into how care is shifting to outpatient settings. Learn more in InspiroGene’s latest CGT Report: https://lnkd.in/gvENNQCf #CellAndGeneTherapy #PatientAccess #CGTLandscape
-
-
Joe DePinto shares five critical supply chain planning insights that every CGT developer needs to consider when bringing their first therapy to market. Read them here: https://lnkd.in/gQP3prgj #CellAndGeneTherapy #CommercialStrategy #CGTCommercialization
-
-
Our 2025 map of qualified treatment centers (QTCs) for #CGT highlights a clear trend: most QTCs are clustered in major metropolitan areas. The solution? Expanding capacity at community sites of care, so patients can receive transformative therapies closer to home. Read more: https://lnkd.in/g5R_aDnb #CellAndGeneTherapy #PatientAccess
-
-
Joe DePinto shared how InspiroGene is helping the #CGT ecosystem prepare for larger patient populations on Pharmacy Podcast Network’s This Week in Pharmacy podcast. Listen to the full episode: https://lnkd.in/eGRaaK5C #PatientAccess #CellAndGeneTherapy
Trust Matters, Cell and Gene, & World Pharmacists Day On "This Week in Pharmacy" for September 26th, we're talking about Trust in Healthcare, World Pharmacists Day, and Cell & Gene Therapy. Today's co-host is Dr. Melissa Smith PharmD, CPH, with Florida PGx Consulting LLC. https://lnkd.in/es5M8P2s First, #TWIRx News - the FDA approves #Inluriyo imlunestrant on 9/25/2025 which is to treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor-1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. (https://lnkd.in/grdGdp_M) Second, Nested Knowledge, Inc. - is going to revolutionize information access and leverage. This is a powerful tool with evidence synthesis tools for medical researchers. This will help accelerate, collaborate, automate and share the latest and personalized treatment plans. (Kevin Kallmes) (https://lnkd.in/gCVzSxT) Next, announcing "Evidence based Podcasting", the new standard in audio learning for Providers and next level in podcast Continuing Medical Education (CME). (https://lnkd.in/eHmXSP3N ) Shout out to Nick Calla with Orsini - Rare Disease Pharmacy Solutions, a leader in rare disease pharmacy solutions, has been chosen by Crinetics Pharmaceuticals, Inc., as a specialty pharmacy partner for PALSONIFY™ (paltusotine), a nonpeptide, selectively-targeted somatostatin receptor type 2 nonpeptide (SST2) agonist. (https://lnkd.in/euDKDJF4) Today we have two guest #Pharmacists to dig into the "Trust in Healthcare" theme of today's #TWIRx -- the godfather of Functional Pharmacy Robert Kress fRx RPh., and Dr. Lauren Castle, PharmD, MS, AFMC - Founder & CEO of Functional Medicine Pharmacists Alliance. Who do you trust? What information is trustworthy and why? Our special feature is updates on 'Cell & Gene Therapy' with McKesson's Head of Cell Gene Advanced Therapies, Joe DePinto at InspiroGene by McKesson! (https://inspirogene.com/) Today's TWIRx is sponsored by 'Sykes & Company, P.A.' the Pharmacy Accounting Jedi Masters and Independent Pharmacy Cooperative (IPC) and how they're revolutionzing digital health and new revenues with the iCare+ System!
Trust Matters, Cell and Gene, & World Pharmacists Day
www.linkedin.com